HCMT
VRTX icon

Highland Capital Management (Tennessee)’s Vertex Pharmaceuticals VRTX Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,236
Closed -$2.9M – 413
2024
Q3 		$2.9M Sell
6,236
-239
-4% -$115K 0.17% 143
2024
Q2 		$3.03M Sell
6,475
-1,256
-16% -$545K 0.18% 138
2024
Q1 		$3.23M Buy
7,731
+35
+0.5% +$14.8K 0.19% 141
2023
Q4 		$3.13M Sell
7,696
-25
-0.3% -$9.23K 0.19% 141
2023
Q3 		$2.68M Sell
7,721
-112
-1% -$39.2K 0.18% 146
2023
Q2 		$2.76M Sell
7,833
-58
-0.7% -$19.5K 0.18% 146
2023
Q1 		$2.49M Sell
7,891
-185
-2% -$55.5K 0.18% 140
2022
Q4 		$2.33M Sell
8,076
-68
-0.8% -$20.7K 0.16% 152
2022
Q3 		$2.36M Buy
8,144
+10
+0.1% +$2.88K 0.18% 142
2022
Q2 		$2.29M Hold
8,134
– – 0.16% 153
2022
Q1 		$2.12M Buy
8,134
+54
+0.7% +$12.8K 0.13% 171
2021
Q4 		$1.77M Sell
8,080
-2
-0% -$389 0.1% 203
2021
Q3 		$1.47M Sell
8,082
-858
-10% -$168K 0.09% 215
2021
Q2 		$1.8M Sell
8,940
-276
-3% -$57.7K 0.11% 193
2021
Q1 		$1.98M Sell
9,216
-777
-8% -$171K 0.12% 187
2020
Q4 		$2.36M Sell
9,993
-443
-4% -$102K 0.15% 162
2020
Q3 		$2.84M Buy
10,436
+136
+1% +$37.5K 0.2% 132
2020
Q2 		$2.99M Buy
10,300
+918
+10% +$249K 0.23% 118
2020
Q1 		$2.23M Buy
+9,382
New +$2.15M 0.21% 117
2018
Q3 		– Sell
-3,198
Closed -$544K – 358
2018
Q2 		$544K Sell
3,198
-44
-1% -$6.82K 0.04% 288
2018
Q1 		$528K Buy
3,242
+460
+17% +$75.1K 0.04% 282
2017
Q4 		$417K Buy
2,782
+116
+4% +$17.2K 0.03% 300
2017
Q3 		$405K Buy
+2,666
New +$401K 0.03% 286

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Highland Capital Management (Tennessee)'s VRTX Position: Q4 2024 in Review

Highland Capital Management (Tennessee) sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 6,236 shares — an estimated $2.9M sold.

Highland Capital Management (Tennessee) first reported a position in VRTX in Q3 2017 and held it in 23 quarters. The position peaked at $3.23M in Q1 2024. 1,558 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Highland Capital Management (Tennessee) reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Highland Capital Management (Tennessee) sold 6,236 Vertex Pharmaceuticals shares in Q4 2024, an estimated $2.9M.
  • Highland Capital Management (Tennessee) first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 23 quarters.
  • Highland Capital Management (Tennessee)'s Vertex Pharmaceuticals position peaked at $3.23M in Q1 2024.
  • 1,558 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q4 2024, filed 23 Jan 2025.